psnl-10q_20220630.htm
false 2022 Q2 0001527753 --12-31 true false true true P5Y http://fasb.org/us-gaap/2022#AccountsPayableCurrent http://fasb.org/us-gaap/2022#AccountsPayableCurrent P6Y10M20D P6Y8M19D P5Y9M21D P5Y6M P5Y6M P5Y6M P5Y6M 0.6970 0.6939 0.6837 0.6806 0.0282 0.0094 0.0162 0.0062 P6Y29D P6Y3M7D P6Y29D P6Y3M7D 0.7156 0.6990 0.7156 0.6990 0.0339 0.0106 0.0339 0.0106 P6M P6M P5M26D P5M26D 0001527753 2022-01-01 2022-06-30 xbrli:shares 0001527753 2022-07-28 iso4217:USD 0001527753 2022-06-30 0001527753 2021-12-31 iso4217:USD xbrli:shares 0001527753 2022-04-01 2022-06-30 0001527753 2021-04-01 2021-06-30 0001527753 2021-01-01 2021-06-30 0001527753 us-gaap:CommonStockMember 2022-03-31 0001527753 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001527753 us-gaap:RetainedEarningsMember 2022-03-31 0001527753 2022-03-31 0001527753 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001527753 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001527753 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001527753 us-gaap:CommonStockMember 2022-06-30 0001527753 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001527753 us-gaap:RetainedEarningsMember 2022-06-30 0001527753 us-gaap:CommonStockMember 2021-03-31 0001527753 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001527753 us-gaap:RetainedEarningsMember 2021-03-31 0001527753 2021-03-31 0001527753 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001527753 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001527753 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001527753 us-gaap:CommonStockMember 2021-06-30 0001527753 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001527753 us-gaap:RetainedEarningsMember 2021-06-30 0001527753 2021-06-30 0001527753 us-gaap:CommonStockMember 2021-12-31 0001527753 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001527753 us-gaap:RetainedEarningsMember 2021-12-31 0001527753 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001527753 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001527753 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001527753 us-gaap:CommonStockMember 2020-12-31 0001527753 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001527753 us-gaap:RetainedEarningsMember 2020-12-31 0001527753 2020-12-31 0001527753 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001527753 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001527753 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001527753 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001527753 psnl:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 psnl:Segment 0001527753 psnl:FollowOnEquityOfferingsMember 2021-01-29 2021-01-29 0001527753 psnl:FollowOnEquityOfferingsMember 2021-01-29 0001527753 us-gaap:OverAllotmentOptionMember 2021-01-29 2021-01-29 0001527753 psnl:AtMarketSalesAgreementMember 2021-12-30 2021-12-30 xbrli:pure 0001527753 2021-01-01 2021-12-31 0001527753 psnl:NateraIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001527753 psnl:NateraIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001527753 psnl:NateraIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-06-30 0001527753 psnl:NateraIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001527753 psnl:UnitedStatesDepartmentOfVeteransAffairsMillionVeteranProgramMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001527753 psnl:UnitedStatesDepartmentOfVeteransAffairsMillionVeteranProgramMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-04-01 2021-06-30 0001527753 psnl:UnitedStatesDepartmentOfVeteransAffairsMillionVeteranProgramMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001527753 psnl:UnitedStatesDepartmentOfVeteransAffairsMillionVeteranProgramMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-06-30 0001527753 psnl:PfizerIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-04-01 2021-06-30 0001527753 psnl:PfizerIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-06-30 0001527753 psnl:PfizerIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-06-30 0001527753 psnl:AbbVieIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001527753 psnl:MerckCoIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-06-30 0001527753 psnl:MerckCoIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001527753 srt:MinimumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001527753 srt:MinimumMember us-gaap:AccountingStandardsUpdate201409Member 2022-01-01 2022-06-30 0001527753 srt:MaximumMember us-gaap:AccountingStandardsUpdate201409Member 2022-01-01 2022-06-30 0001527753 psnl:VeteransAffairsMillionVeteranProgramMember 2022-04-01 2022-06-30 0001527753 psnl:VeteransAffairsMillionVeteranProgramMember 2021-04-01 2021-06-30 0001527753 psnl:VeteransAffairsMillionVeteranProgramMember 2022-01-01 2022-06-30 0001527753 psnl:VeteransAffairsMillionVeteranProgramMember 2021-01-01 2021-06-30 0001527753 psnl:AllOtherCustomersMember 2022-04-01 2022-06-30 0001527753 psnl:AllOtherCustomersMember 2021-04-01 2021-06-30 0001527753 psnl:AllOtherCustomersMember 2022-01-01 2022-06-30 0001527753 psnl:AllOtherCustomersMember 2021-01-01 2021-06-30 0001527753 srt:MaximumMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember psnl:SignificantCustomersMember 2022-04-01 2022-06-30 0001527753 srt:MaximumMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember psnl:SignificantCustomersMember 2021-04-01 2021-06-30 0001527753 srt:MaximumMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember psnl:SignificantCustomersMember 2022-01-01 2022-06-30 0001527753 srt:MaximumMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember psnl:SignificantCustomersMember 2021-01-01 2021-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001527753 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001527753 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001527753 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001527753 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2022-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001527753 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001527753 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001527753 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001527753 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001527753 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001527753 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2021-12-31 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001527753 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001527753 psnl:LongTermInvestmentsMember 2022-06-30 0001527753 srt:MinimumMember 2022-01-01 2022-06-30 0001527753 srt:MaximumMember 2022-01-01 2022-06-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-04-30 psnl:Payment 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:ComputerEquipmentMember 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember us-gaap:ComputerEquipmentMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember psnl:TrancheOneMember us-gaap:ComputerEquipmentMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember psnl:TrancheTwoMember us-gaap:ComputerEquipmentMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember psnl:TrancheThreeMember us-gaap:ComputerEquipmentMember 2021-04-01 2021-04-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember 2022-06-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember 2022-04-01 2022-06-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember 2022-01-01 2022-06-30 0001527753 psnl:PaymentAgreementWithFinancingEntityMember 2021-12-31 utr:sqft 0001527753 2015-02-28 0001527753 2021-05-31 0001527753 2020-04-01 2020-04-30 0001527753 2021-05-01 2021-05-31 0001527753 2020-04-30 0001527753 psnl:CoLocatedDataCenterSpaceMember 2019-08-01 2019-08-31 0001527753 psnl:CoLocatedDataCenterSpaceMember 2022-01-01 2022-06-30 0001527753 psnl:CoLocatedDataCenterSpaceMember 2019-08-31 0001527753 psnl:FutureCorporateHeadquartersAndExpandedLaboratoryFacilityMember 2021-08-31 0001527753 psnl:FutureCorporateHeadquartersAndExpandedLaboratoryFacilityMember 2021-08-01 2021-08-31 0001527753 psnl:FutureCorporateHeadquartersAndExpandedLaboratoryFacilityMember 2021-08-01 2022-06-30 0001527753 psnl:FutureCorporateHeadquartersAndExpandedLaboratoryFacilityMember 2022-01-01 2022-06-30 0001527753 psnl:ChinaOperationsMember 2022-06-30 0001527753 psnl:ChinaOperationsMember 2022-01-01 2022-06-30 0001527753 psnl:TwoThousandElevenAndTwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2021-12-31 0001527753 psnl:TwoThousandElevenAndTwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2022-01-01 2022-06-30 0001527753 psnl:TwoThousandElevenAndTwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2022-06-30 0001527753 psnl:TwoThousandElevenAndTwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2021-01-01 2021-12-31 0001527753 srt:MinimumMember 2022-04-01 2022-06-30 0001527753 srt:MinimumMember 2021-04-01 2021-06-30 0001527753 srt:MinimumMember 2021-01-01 2021-06-30 0001527753 srt:MaximumMember 2022-04-01 2022-06-30 0001527753 srt:MaximumMember 2021-04-01 2021-06-30 0001527753 srt:MaximumMember 2021-01-01 2021-06-30 0001527753 psnl:PerformanceBasedStockOptionMember 2022-06-30 0001527753 psnl:PerformanceBasedStockOptionMember 2022-01-01 2022-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember psnl:TwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2021-12-31 0001527753 us-gaap:RestrictedStockUnitsRSUMember psnl:TwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2022-01-01 2022-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember psnl:TwoThousandNineteenEquityIncentivePlanAndTwoThousandTwentyInducementPlanMember 2022-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001527753 psnl:TwoThousandNineteenEmployeeStockPurchasePlanMember 2021-01-01 2021-06-30 0001527753 psnl:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-04-01 2022-06-30 0001527753 psnl:TwoThousandNineteenEmployeeStockPurchasePlanMember 2021-04-01 2021-06-30 0001527753 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001527753 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001527753 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001527753 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001527753 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2022-04-01 2022-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2021-04-01 2021-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2021-01-01 2021-06-30 0001527753 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0001527753 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001527753 us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0001527753 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001527753 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001527753 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001527753 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001527753 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001527753 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0001527753 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0001527753 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0001527753 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-06-30 0001527753 psnl:OptionsToPurchaseCommonStockMember 2022-04-01 2022-06-30 0001527753 psnl:OptionsToPurchaseCommonStockMember 2021-04-01 2021-06-30 0001527753 psnl:OptionsToPurchaseCommonStockMember 2022-01-01 2022-06-30 0001527753 psnl:OptionsToPurchaseCommonStockMember 2021-01-01 2021-06-30 0001527753 psnl:UnvestedRestrictedStockUnitsMember 2022-04-01 2022-06-30 0001527753 psnl:UnvestedRestrictedStockUnitsMember 2021-04-01 2021-06-30 0001527753 psnl:UnvestedRestrictedStockUnitsMember 2022-01-01 2022-06-30 0001527753 psnl:UnvestedRestrictedStockUnitsMember 2021-01-01 2021-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2022-04-01 2022-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2021-04-01 2021-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 0001527753 psnl:EmployeeStockPurchasePlanMember 2021-01-01 2021-06-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 001-38943

 

Personalis, Inc.

(Exact Name of registrant as specified in its charter)

 

 

Delaware

27-5411038

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

1330 O’Brien Drive

Menlo Park, California 94025

94025

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (650) 752-1300

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001

 

PSNL

 

The Nasdaq Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

         ☒

  

Accelerated filer

 

Non-accelerated filer

 

         ☐

  

Smaller reporting company

 

Emerging growth company

 

          

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No   

The number of shares of registrant’s Common Stock outstanding as of July 28, 2022 was 45,918,389.

 


 

PERSONALIS, INC.

 

Form 10-Q

For the Quarterly Period Ended June 30, 2022

 

TABLE OF CONTENTS

 

 

 

 

 

Page

 

Special Note Regarding Forward-Looking Statements

3

 

 

 

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements

4

 

Condensed Consolidated Balance Sheets

4

 

Condensed Consolidated Statements of Operations

5

 

Condensed Consolidated Statements of Comprehensive Loss

6

 

Condensed Consolidated Statements of Stockholders’ Equity

7

 

Condensed Consolidated Statements of Cash Flows

9

 

Notes to Unaudited Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

29

Item 4.

Controls and Procedures

29

 

 

 

PART II—OTHER INFORMATION

Item 1.

Legal Proceedings

30

Item 1A.

Risk Factors

30

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

70

Item 3.

Defaults Upon Senior Securities

70

Item 4.

Mine Safety Disclosures

70

Item 5.

Other Information

70

Item 6.

Exhibits

71

 

Signatures

72

 

2


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following:

 

 

the evolution of cancer therapies and market adoption of our services and products;

 

estimates of our total addressable market, future revenue, expenses, capital requirements, and our needs for additional financing;

 

our ability to enter into and compete in new markets;

 

the impact of the ongoing COVID-19 pandemic on our business, our customers’ and suppliers’ businesses and the general economy;

 

our ability to compete effectively with existing competitors and new market entrants;

 

our ability to scale our infrastructure;

 

our ability to manage and grow our business by expanding our sales to existing customers or introducing our services and products to new customers;

 

our ability to establish and maintain intellectual property protection for our services and products or avoid claims of infringement;

 

potential effects of extensive government regulation;

 

our ability to hire and retain key personnel;

 

our ability to obtain financing in future offerings;

 

the volatility of the trading price of our common stock;

 

our belief that approval of personalized cancer therapies by the Food and Drug Administration may drive benefits to our business;

 

expectations regarding our relationship with the U.S. Department of Veterans Affairs’ Million Veteran Program; and

 

our ability to maintain proper and effective internal controls.

Actual events or results may differ from those expressed in forward-looking statements. As such, you should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, operating results, prospects, strategy, and financial needs. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions, and other factors described in the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Moreover, we operate in a highly competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information, actual results, revised expectations, or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to the “company,” “Personalis,” “we,” “us” and “our” refer to Personalis, Inc.

 

 

 

3


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

PERSONALIS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in thousands, except share and per share data)

 

 

 

June 30, 2022

 

 

December 31, 2021

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

86,731

 

 

$

105,585

 

Short-term investments

 

 

146,759

 

 

 

181,479

 

Accounts receivable, net

 

 

12,877

 

 

 

18,468

 

Inventory and other deferred costs

 

 

7,885

 

 

 

5,610

 

Prepaid expenses and other current assets

 

 

5,788

 

 

 

7,089

 

Total current assets

 

 

260,040

 

 

 

318,231

 

Property and equipment, net

 

 

47,585

 

 

 

19,650

 

Operating lease right-of-use assets

 

 

45,915

 

 

 

53,822

 

Other long-term assets

 

 

4,439

 

 

 

4,825

 

Total assets

 

$

357,979

 

 

$

396,528

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

21,395

 

 

$

9,221

 

Accrued and other current liabilities

 

 

19,755

 

 

 

18,110

 

Contract liabilities

 

 

356

 

 

 

3,982

 

Total current liabilities

 

 

41,506

 

 

 

31,313

 

Long-term operating lease liabilities

 

 

51,836

 

 

 

52,797

 

Other long-term liabilities

 

 

5

 

 

 

2,117

 

Total liabilities

 

 

93,347

 

 

 

86,227

 

Commitments and Contingencies (Note 9)

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued

 

 

 

 

 

 

Common stock, $0.0001 par value — 200,000,000 shares authorized; 45,891,458 and 44,904,512 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

568,741

 

 

 

557,558

 

Accumulated other comprehensive loss

 

 

(1,264

)

 

 

(166

)

Accumulated deficit

 

 

(302,850

)

 

 

(247,095

)

Total stockholders’ equity

 

 

264,632

 

 

 

310,301

 

Total liabilities and stockholders’ equity

 

$

357,979

 

 

$

396,528

 

 

 

See notes to condensed consolidated financial statements.

 

4


 

PERSONALIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in thousands, except share and per share data)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenue

 

$

18,240

 

 

$

21,670

 

 

$

33,467

 

 

$

42,551

 

Costs and expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

13,959

 

 

 

13,502

 

 

 

24,908

 

 

 

26,956

 

Research and development

 

 

16,288

 

 

 

11,687

 

 

 

33,386

 

 

 

21,183

 

Selling, general and administrative

 

 

15,874

 

 

 

11,428

 

 

 

31,360

 

 

 

21,849

 

Total costs and expenses

 

 

46,121

 

 

 

36,617

 

 

 

89,654

 

 

 

69,988

 

Loss from operations

 

 

(27,881

)

 

 

(14,947

)

 

 

(56,187

)

 

 

(27,437

)

Interest income

 

 

349

 

 

 

103

 

 

 

493

 

 

 

198

 

Interest expense

 

 

(50

)

 

 

(65

)

 

 

(109

)

 

 

(65

)

Other income (expense), net

 

 

50

 

 

 

(36

)

 

 

69

 

 

 

(48

)

Loss before income taxes

 

 

(27,532

)

 

 

(14,945

)

 

 

(55,734

)

 

 

(27,352

)

Provision for income taxes

 

 

14

 

 

 

8

 

 

 

21

 

 

 

5

 

Net loss

 

$

(27,546

)

 

$

(14,953

)

 

$

(55,755

)

 

$

(27,357

)

Net loss per share, basic and diluted

 

$

(0.60

)

 

$

(0.34

)

 

$

(1.23

)

 

$

(0.63

)

Weighted-average shares outstanding, basic and diluted

 

 

45,637,838

 

 

 

43,960,794

 

 

 

45,316,795

 

 

 

43,113,195

 

 

See notes to condensed consolidated financial statements.

5


PERSONALIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

(in thousands)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net loss

 

$

(27,546

)

 

$

(14,953

)

 

$

(55,755

)

 

$

(27,357

)

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

(194

)

 

 

19

 

 

 

(202

)

 

 

21

 

Change in unrealized gain (loss) on available-for-sale debt securities

 

 

(195

)

 

 

4

 

 

 

(896

)

 

 

(25

)

Comprehensive loss

 

$

(27,935

)

 

$

(14,930

)

 

$

(56,853

)

 

$

(27,361

)

 

See notes to condensed consolidated financial statements.

 

6


 

PERSONALIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)

For the Three Months Ended June 30, 2022 and 2021

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance—March 31, 2022

 

 

45,250,087

 

 

$

5

 

 

$

562,889

 

 

$

(875

)

 

$

(275,304

)

 

$

286,715

 

Proceeds from exercise of stock options

 

 

195,839

 

 

 

 

 

 

463

 

 

 

 

 

 

 

 

 

463

 

Proceeds from ESPP purchases

 

 

204,775

 

 

 

 

 

 

974

 

 

 

 

 

 

 

 

 

974

 

Restricted stock units vested

 

 

240,757

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,415

 

 

 

 

 

 

 

 

 

4,415

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

(194

)

 

 

 

 

 

(194

)

Unrealized loss on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

(195

)

 

 

 

 

 

(195

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(27,546

)

 

 

(27,546

)

Balance—June 30, 2022

 

 

45,891,458

 

 

$

5

 

 

$

568,741

 

 

$

(1,264

)

 

$

(302,850

)

 

$

264,632

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance—March 31, 2021

 

 

43,798,661

 

 

$

4

 

 

$

542,694

 

 

$

(5

)

 

$

(194,273

)

 

$

348,420

 

Proceeds from exercise of stock options

 

 

270,912

 

 

 

 

 

 

466

 

 

 

 

 

 

 

 

 

466

 

Proceeds from ESPP purchases

 

 

57,001

 

 

 

 

 

 

1,191

 

 

 

 

 

 

 

 

 

1,191

 

Restricted stock units vested

 

 

83,394

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

3,600

 

 

 

 

 

 

 

 

 

3,600

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

19

 

 

 

 

 

 

19

 

Unrealized gain on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

4

 

 

 

 

 

 

4

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(14,953

)

 

 

(14,953

)

Balance—June 30, 2021

 

 

44,209,968

 

 

$

4

 

 

$

547,951

 

 

$

18

 

 

$

(209,226

)

 

$

338,747

 

 

See notes to condensed consolidated financial statements.

7


PERSONALIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)

For the Six Months Ended June 30, 2022 and 2021

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance—December 31, 2021

 

 

44,904,512

 

 

$

4

 

 

$

557,558

 

 

$

(166

)

 

$

(247,095

)

 

$

310,301

 

Proceeds from exercise of stock options

 

 

475,044

 

 

 

1

 

 

 

978

 

 

 

 

 

 

 

 

 

979

 

Proceeds from ESPP purchases

 

 

204,775

 

 

 

 

 

 

974

 

 

 

 

 

 

 

 

 

974

 

Restricted stock units vested

 

 

307,127

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

9,231

 

 

 

 

 

 

 

 

 

9,231

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

(202

)

 

 

 

 

 

(202

)

Unrealized loss on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

(896

)

 

 

 

 

 

(896

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(55,755

)

 

 

(55,755

)

Balance—June 30, 2022

 

 

45,891,458

 

 

$

5

 

 

$

568,741

 

 

$

(1,264

)

 

$

(302,850

)

 

$

264,632

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance—December 31, 2020

 

 

39,105,548

 

 

$

4

 

 

$

376,788

 

 

$

22

 

 

$

(181,869

)

 

$

194,945

 

Proceeds from follow-on equity offering, net of offering costs

 

 

4,542,500

 

 

 

 

 

 

161,916

 

 

 

 

 

 

 

 

 

161,916

 

Proceeds from exercise of stock options

 

 

384,938

 

 

 

 

 

 

1,399

 

 

 

 

 

 

 

 

 

1,399

 

Proceeds from ESPP purchases

 

 

57,001

 

 

 

 

 

 

 

1,191

 

 

 

 

 

 

 

 

 

1,191

 

Restricted stock units vested

 

 

119,981

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

6,657

 

 

 

 

 

 

 

 

 

6,657

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

21

 

 

 

 

 

 

21

 

Unrealized loss on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

(25

)

 

 

 

 

 

(25

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(27,357

)

 

 

(27,357

)

Balance—June 30, 2021

 

 

44,209,968

 

 

$

4

 

 

$

547,951

 

 

$

18

 

 

$

(209,226

)

 

$

338,747

 

 

See notes to condensed consolidated financial statements.

8


 

 

PERSONALIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(55,755

)

 

$

(27,357

)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

9,231

 

 

 

6,657

 

Depreciation and amortization

 

 

3,594

 

 

 

2,909

 

Noncash operating lease cost

 

 

2,443

 

 

 

856

 

Amortization of premium on short-term investments

 

 

481

 

 

 

1,012

 

Other

 

 

19

 

 

 

71

 

Changes in operating assets and liabilities